Reduce issues with trial and error prescribing, and reduce adverse medication reactions with Amplis.Offer Amplis in your clinic
CNSdose expands medication guidance from leading antidepressant guidance to expanded guidance for Geriatrics, Primary Care, Neurology, Internal Medicine, Psychiatry and more. Amplis was developed in partnership with Coriell Life Sciences.
Leading blood-brain-barrier knowledge
The blood-brain-barrier is a filtering system of the small blood vessels that carry blood to the brain and spinal cord tissue, blocking the passage of certain substances.
CNSdose has a world-leading understanding of how genetics influence this system. More specifically, CNSdose has an advanced understanding of the genetics of the ABC transporter pumps.
CNSdose uses the key to the blood brain barrier to create the Amplis report
We have the first positive clinical trial for antidepressant treatment. Evidence indicates our gene-guided treatment can double the likelihood of recovery. A review by the US Department of Veterans Affairs Health Administration said 'Amplis (antidepressant guidance) has the most favorable preliminary findings' based on this trial.
Depression is commonly associated with chronic diseases. Individuals diagnosed with common chronic conditions such as heart disease, arthritis, pain disorders, and chronic lung disease are at increased risk for developing depression. Individuals diagnosed with depression, are at increased risk for developing chronic conditions such as heart disease and diabetes. Amplis provides genetic guidance for the better management of these co-occurring chronic conditions.
With over 50% of US Adults taking two or more medications and 28% being hospitalized due to adverse drug interactions, polypharmacy issues are on the rise.
Amplis Report reduces the likelihood of adverse drug interactions and provides you with medication risks based on your patient’s genetics and lifestyle factors to help guide your prescription decisions.
80% of patients with diabetes and 45% with coronary artery disease will experience depression but it can take months to find relief. Amplis Report provides you with an analysis of your patient’s medication profile to fulfill your prescriber needs.
The leading cause of disability in the US. Moreover, depression is a common co-occurrence with other mental health conditions such that 57% of US adults with schizophrenia have comorbid depression. Amplis is based upon a cutting-edge knowledge of both liver and blood-brain-barrier metabolism to help you find more effective medications fast.